



IPO INSIGHTS



Inventurus Knowledge Solutions Limited

Issue Dates - Opens: 12-12-2024 | Closes: 16-12-2024

IPO Note	<ol style="list-style-type: none"> Inventurus Knowledge Solutions Limited (IKS Health) provides services to healthcare enterprises such as handling administrative chores/work. The Company helps doctors and other healthcare providers by handling their paperwork and administrative tasks.
Rating	★★ (Average)

IPO SNAPSHOT

Issue Size	₹2497.92 Crores
Issue Type	Book Built Issue IPO
Fresh Issue	-
Offer for Sale	₹2497.92 Crores
Face Value Per Share	₹1
Price Band Per Share	₹1265 to ₹1329
Minimum Lot Size	11 Shares
Listing On	BSE, NSE
Registrar to the Issue	Link Intime India Private Ltd

IPO SNAPSHOT- Sagility India Limited

<p>About the Company</p>	<ul style="list-style-type: none"> ▪ Incorporated in 2006 ▪ Inventurus Knowledge Solutions Health offers services such as clinical support, medical documentation management, virtual medical scribing and more. ▪ The Company is a healthcare technology company that helps make it easier and faster for patients to get the care they need while reducing the administrative burden on healthcare providers. ▪ Inventurus Knowledge Solutions Limited offer a platform that enables healthcare enterprises in outpatient and inpatient care. ▪ The Company is a partner for outpatient and inpatient care organizations, enabling healthcare organizations deliver superior clinical care, improve population health outcomes, and transition to the “fee for value” model while optimizing their revenue and reducing operating costs. ▪ The Company is a technology-enabled healthcare solutions provider and offer a care enablement platform assisting physician enterprises in the US, Canada and Australia, with a focus on the US markets. 																														
<p>Competitive Strengths</p>	<ul style="list-style-type: none"> ▪ Comprehensive one-stop platform with diversified offerings across the outpatient and inpatient care value chain serving key stakeholders such as patients, physicians, nurses and healthcare organizations. ▪ Leveraging digital evolution, transformation and automation technologies to create sustained value based on outcomes delivered. ▪ Strong brand driven by clinical thought leadership through IKS Advisory Board, a healthcare industry leadership forum, and partnerships with industry players and evident through multiple awards and recognitions. ▪ Marquee large enterprise clientele that include academic medical centres and healthcare systems, multispecialty and single-specialty medical groups, ancillary healthcare organizations, value enablers, and other outpatient healthcare delivery organizations and client stickiness reflected in revenues from repeat clients of over 90.00% in the last three Fiscals. ▪ Sustainable and scalable business model offering clients flexibility and cost-savings and high-touch engagement through access to project executive sponsors and leadership teams creating cross-selling opportunities. ▪ Healthy financial performance with growth and improving margins ▪ Experienced and entrepreneurial driven leadership team 																														
<p>Financials (₹ in Crores)</p>	<table border="1"> <thead> <tr> <th>Particulars</th> <th>31-3-2022</th> <th>31-3-2023</th> <th>31-03-2024</th> <th>Y-o-Y</th> </tr> </thead> <tbody> <tr> <td>Revenue</td> <td>763.63</td> <td>1031.30</td> <td>1817.29</td> <td>76%</td> </tr> <tr> <td>EBITDA</td> <td>297.18</td> <td>391.31</td> <td>520.30</td> <td>33%</td> </tr> <tr> <td>EBITDA Margin</td> <td>38.9%</td> <td>37.9%</td> <td>28.6%</td> <td></td> </tr> <tr> <td>PAT</td> <td>232.97</td> <td>305.23</td> <td>370.49</td> <td>21%</td> </tr> <tr> <td>PAT Margin</td> <td>30.5%</td> <td>29.6%</td> <td>20.4%</td> <td></td> </tr> </tbody> </table>	Particulars	31-3-2022	31-3-2023	31-03-2024	Y-o-Y	Revenue	763.63	1031.30	1817.29	76%	EBITDA	297.18	391.31	520.30	33%	EBITDA Margin	38.9%	37.9%	28.6%		PAT	232.97	305.23	370.49	21%	PAT Margin	30.5%	29.6%	20.4%	
Particulars	31-3-2022	31-3-2023	31-03-2024	Y-o-Y																											
Revenue	763.63	1031.30	1817.29	76%																											
EBITDA	297.18	391.31	520.30	33%																											
EBITDA Margin	38.9%	37.9%	28.6%																												
PAT	232.97	305.23	370.49	21%																											
PAT Margin	30.5%	29.6%	20.4%																												
<p>Valuation</p>	<ul style="list-style-type: none"> ▪ Attributing Annualized FY23 Earnings asking P/E = 61.55 																														
<p>Peers</p>	<ul style="list-style-type: none"> ▪ No listed peers 																														
<p>Promoters</p>	<ul style="list-style-type: none"> ▪ Sachin Gupta ▪ Rekha Jhunjunwala ▪ Aryaman Jhunjunwala Discretionary Trust ▪ Aryavir Jhunjunwala Discretionary Trust ▪ Nishtha Jhunjunwala Discretionary Trust 																														
<p>Objects of the issue</p>	<ul style="list-style-type: none"> ▪ The Company will not receive any proceeds from the Offer. 																														

DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors should not rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

